» Articles » PMID: 23125116

Evaluation of Expression Profiles of Hematopoietic Stem Cell, Endothelial Cell, and Myeloid Cell Antigens in Spontaneous and Chemically Induced Hemangiosarcomas and Hemangiomas in Mice

Overview
Journal Toxicol Pathol
Publisher Sage Publications
Date 2012 Nov 6
PMID 23125116
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

It is unclear whether the process of spontaneous and chemically induced hemangiosarcoma and hemangioma formation in mice involves the transformation of differentiated endothelial cells (ECs) or recruitment of multipotential bone marrow-derived hematopoietic stem cells or endothelial progenitor cells (EPCs), which show some degree of endothelial differentiation. In the present study, immunohistochemical staining for hematopoietic stem cell markers (CD45 and CD34), EC markers (vascular endothelial growth factor receptor 2 [VEGFR2], CD31, and factor VIII-related antigen), and a myeloid lineage marker (CD14) was employed to better define the origin of hemangiosarcomas and hemangiomas in mice. Staining was negative for CD45, factor VIII-related antigen, and CD14 and positive for CD34, VEGFR2, and CD31, indicating that mouse hemangiosarcomas and hemangiomas are composed of cells derived from EPCs expressing CD34, VEGFR2, and CD31 but not factor VIII-related antigen. The lack of CD45 expression suggests that mouse vascular tumors may arise from EPCs that are at a stage later than hematopoietic stem cells. Since factor VIII-related antigen expression is known to occur later than CD31 expression in EPCs, our observations may indicate that these tumor cells are arrested at a stage prior to complete differentiation.  In addition, myeloid lineage cells do not appear to contribute to hemangiosarcoma and hemangioma formation in mice.

Citing Articles

PIK3CA mutation fortifies molecular determinants for immune signaling in vascular cancers.

Lee D, Kozurek E, Abdullah M, Wong E, Li R, Liu Z Cancer Gene Ther. 2024; 32(2):254-267.

PMID: 39709507 PMC: 11839470. DOI: 10.1038/s41417-024-00867-4.


Feline Oncogenomics: What Do We Know about the Genetics of Cancer in Domestic Cats?.

Ludwig L, Dobromylskyj M, Wood G, van der Weyden L Vet Sci. 2022; 9(10).

PMID: 36288160 PMC: 9609674. DOI: 10.3390/vetsci9100547.


Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro.

Majeed Y, Upadhyay R, Alhousseiny S, Taha T, Musthak A, Shaheen Y Sci Rep. 2019; 9(1):6316.

PMID: 31004117 PMC: 6474884. DOI: 10.1038/s41598-019-42838-y.


Magnetic resonance imaging and immunohistochemistry of primary vertebral hemangiosarcoma in a dog and implications for diagnosis and therapy.

Perez-Martinez C, Regueiro-Purrinos M, Fernandez-Martinez B, Altonaga J, Gonzalo-Orden J, Garcia-Iglesias M Can Vet J. 2016; 57(12):1247-1250.

PMID: 27928170 PMC: 5109625.


Evaluation of potential activity of luseogliflozin on vascular proliferation in the mesenteric lymph node with or without vascular tumors in Sprague-Dawley rats in a carcinogenicity study.

Sasaki M, Sakurai T, Ishii A, Matsue K, Nakanishi Y, Tsutsumi S J Toxicol Pathol. 2016; 29(2):85-93.

PMID: 27182112 PMC: 4865605. DOI: 10.1293/tox.2015-0054.